**Specifications Table**TableSubject area*Biology*More specific subject area*Bioengineering human heart matrix*Type of data*Table, image, text file, figure*How data was acquired*Echocardiography (General Electric),* linear mixed-effects models (LME, S-Plus version 8.0, Tibco Software) and angiography (Siemens)Data format*Analyzed, processed*Experimental factors*Human hearts used in the study were not suitable for transplantation.*Experimental features*Heart decellularization perfusion was performed to remove cells but retain the extracellular matrix scaffold. Characteristics of the scaffold valves, chambers and vasculature were assessed using echocardiography, pressure-volume measurements and coronary angiography. The effect of the human scaffold on the differentiation of human cardiac progenitor cells was also analyzed with different primers*Data source location*Madrid, Spain*Data accessibility*Within this article*

**Value of the data**•The data provides the schematic information of a decellularization heart perfusion technique that could be followed as a standardized technique for additional decellularization studies.•The data provides the detail information of the characteristics of donors and heart scaffolds. These physiologic data will provide researchers with important age- and sex-specific reference ranges for evaluating experimental results.•It also provides the basis of different experiments for a clear demonstration of valve competence, coronary angiography assessment and pressure-volume measurements. These novel assays could be useful tools for the in vitro evaluation of decellularized heart scaffolds.•The data provides the primers used to assess cardiac gene expression in human cardiac progenitor cells grown on human decellularized extracellular matrices. The primers profile data could be used to identify cardiac cell differentiation.

1. Data {#s0005}
=======

Dataset provided in this article shows the perfusion decellularization protocol we used to remove the cells from 39 human hearts while retaining the extracellular matrix [@bib1]. The characteristics of the decellularized valves and anatomical aspects of the decellularized cardiac vessels were assessed by using echocardiography and coronary angiography, respectively. In addition, the passive pressure-volume relationship of the left and right ventricle was measured in 8 human hearts before and after decellularization. Finally, primers used to assess cardiac gene expression in human cardiac progenitor cells grown on human decellularized extracellular matrix are described.

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Heart decellularization technique {#s0015}
--------------------------------------

To remove cells but retain the extracellular matrix (ECM) we applied our previously described perfusion decellularization technique, [@bib2] with 1% sodium dodecyl sulfate (SDS) detergent in deionized water via antegrade coronary perfusion of the ascending aorta. Schematic of perfusion decellularization of human heart is shown in [Fig. 1](#f0005){ref-type="fig"}, Panel A. Perfusion pressure is monitored to perfuse the heart at \~80--100 mm Hg (normal blood pressure) and is changed by altering the height of the dispensing container that feeds the decellularization or washing reagents into the aorta. During the decellularization period ([Fig. 1](#f0005){ref-type="fig"}, Panels B to E) over 72--96 h, there is a loss of color as decellularization proceeds first from the thinnest regions (great vessels and atria) and progresses toward the thickest areas of the heart so that the decellularized parts become more translucent and devoid of most color.

2.2. Characteristics of donors and heart scaffolds {#s0020}
--------------------------------------------------

Characteristics of donors, donor hearts, scaffolds and perfusion decellularization process are shown in [Table 1](#t0005){ref-type="table"}. Thirty-nine human hearts were decellularized and 13 human hearts were used as controls.

2.3. Valve competence evaluation {#s0025}
--------------------------------

Macroscopic valve inspection was performed by cardiac surgeons and by echocardiography. Valve obstruction was easily excluded by macroscopic valve inspection of the valves. The semilunar valves (pulmonary and aortic) prevented retrograde flow back into the ventricles by a simply maneuver of filling with saline the ascending aorta and the pulmonary arteries. The atrioventricular valves (tricuspid and mitral) were evaluated with echocardiography filling the LV and RV through a 5-French intravascular sheath, inserted across the hermetically closed sutured aortic or pulmonary valves, with isotonic saline using 60 ml syringes ([Fig. 2](#f0010){ref-type="fig"}). Systole and diastole was modified by aspiration or injection of saline through the syringes helped by an external compression of the ventricles with the hand. During echocardiography evaluation, the scaffolds were submerged in deionized water. We obtained images with a broadband 14 MHz transducer (General Electric).

2.4. Integrity of epicardial and myocardial coronary circulation {#s0030}
----------------------------------------------------------------

Simultaneous angiography of the left and right coronary artery was assed to test the integrity of epicardial and myocardial coronary circulation of the whole decellularized human hearts. Controls and decellularized hearts were positioned in a foam mold, with a similar height to the anteroposterior thorax length, where the heart shape was dug ([Fig. 3](#f0015){ref-type="fig"}, Panel A and B). To record the coronary angiographic sequences we used an Artis Zee biplane system (Siemens Healthcare) ([Fig. 3](#f0015){ref-type="fig"}, Panel B). Both coronary ostium were cannulated with a conventional irrigating DeBakey heparing cannula (3 mm tip, 2 ½\", 6.3 cm length, Pilling) and simultaneous angiography injections were performed using a conventional mechanical injector pump ([Fig. 3](#f0015){ref-type="fig"}, Panel C-D). We also cannulated the coronary sinus with a conventional retrograde cannula (Medtronic) in order to simultaneously drain the injected contrast media (iodixanol, Visipaque^TM^, General Electric).

2.5. Pressure--volume measurements {#s0035}
----------------------------------

We studied the relative contributions of the ECM to overall passive mechanical global properties of the left ventricle (LV) and right ventricle (RV) chambers. Mechanical properties of the decellularized human hearts were compared to the intact heart before decellularization both for the LV and RV, slightly modifying previously reported methods. [@bib3], [@bib4], [@bib5] LV and RV are hermetically closed suturing aortic ([Fig. 4](#f0020){ref-type="fig"}, Panel A), pulmonary, mitral and tricuspid valves in a fully closed position. A 5-French intravascular sheath is inserted across the aortic ([Fig. 4](#f0020){ref-type="fig"}, Panel B) and pulmonary valve depending whether LV or RV pressure-volume measurements are calculated. Non- compliant polyethylene balloons are inserted across the aortic or pulmonary valves and hermetically attached to the 5-French intravascular sheath because saline leakage was observed in scaffolds ([Fig. 4](#f0020){ref-type="fig"}, panel C). A 5-French high-fidelity micromanometer (Millar-Instrument) was placed inside the balloon and connected to a 3-port manifold ([Fig. 4](#f0020){ref-type="fig"}, Panel D). Pressure and volume are then modified by aspiration followed by slow injection of isotonic saline using 60 ml syringes attached to the manifold ([Fig. 4](#f0020){ref-type="fig"}, Panel E). Differences in repated measures obtained during pre- and post-decellularization of each specimen are assessed by linear mixed-effects models (LME, S-Plus version 8.0, Tibco Software)([Fig. 2](#f0010){ref-type="fig"}, Panel F).

2.6. Cardiac gene expression {#s0040}
----------------------------

Primers used to assess cardiac gene expression in human cardiac progenitor cells grown on human decellularized ECM for 21 days are shown in [Table 2.](#t0010){ref-type="table"}

2.7. Summarizing table {#s0045}
----------------------

[Table 3](#t0015){ref-type="table"} summarizes critical steps and troubleshooting, number of samples analyzed and homogeneity results of the aforementioned principal protocols.

Appendix A. Supplementary material {#s0060}
==================================
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###### 

Characteristics of donors, donor hearts, scaffolds, and perfusion decellularization process.

Table 1

  **Sex**   **Age**   **Heart weight**   **Scaffold weight**   **Time to start of decellularization**   **Days of decellularization**
  --------- --------- ------------------ --------------------- ---------------------------------------- -------------------------------
  Male      50        558                452                   9 h                                      4
  Male      73        466                436                   12 h                                     7
  Female    58        332                224                   24 h                                     4
  Female    50        369                292                   24 h                                     7
  Male      80        398                327                   24 h                                     7
  Female    67        488                457                   24 h                                     8
  Female    87        358                Control               Control                                  Control
  Female    35        267                Control               Control                                  Control
  Female    54        587                522                   9 h                                      7
  Male      59        550                500                   13 h                                     8
  Male      49        380                351                   8 h                                      4
  Male      76        343                288                   24 h                                     4
  Female    68        526                432                   3 days                                   5
  Female    65        314                283                   3 days                                   4
  Female    17        231                189                   8 h                                      5
  Male      57        671                657                   5 h                                      5
  Male      66        435                344                   24 h                                     4
  Male      61        512                Control               Control                                  Control
  Male      41        398                Control               Control                                  Control
  Male      41        680                572                   12 h                                     7
  Female    72        284                Control               Control                                  Control
  Male      43        353                300                   24 h                                     4
  Male      58        376                331                   4 days                                   4
  Male      59        432                376                   24 h                                     4
  Male      57        326                Control               Control                                  Control
  Male      46        358                Control               Control                                  Control
  Male      30        291                Control               Control                                  Control
  Male      78        298                Control               Control                                  Control
  Male      70        644                528                   10 h                                     6
  Male      78        430                354                   5 days                                   4
  Male      55        252                214                   12 h                                     7
  Female    32        271                171                   12 h                                     3
  Male      56        303                249                   2 days                                   7
  Female    60        404                334                   60 h                                     5
  Female    66        335                Control               Control                                  Control
  Female    80        464                361                   12 h                                     7
  Male      58        419                279                   10 h                                     6
  Male      73        515                439                   12 h                                     4
  Male      52        457                435                   18 h                                     8
  Male      70        464                393                   12 h                                     8
  Male      52        565                373                   24 h                                     6
  Male      54        362                Control               Control                                  Control
  Male      59        410                Control               Control                                  Control
  Male      67        373                306                   12 h                                     8
  Female    64        305                244                   12 h                                     8
  Female    64        321                238                   18 h                                     8
  Female    63        526                418                   18 h                                     4
  Female    38        343                Control               Control                                  Control
  Female    56        265                214                   15 h                                     8
  Female    65        327                295                   18 h                                     8
  Male      52        682                532                   12 h                                     8
  Male      70        677                525                   12 h                                     8

###### 

Primers used to assess cardiac muscle gene expression in hCPCs grown on human dECM for 21 days.

Table 2

  **Gene**     **Sense**                        **Anti-Sense**
  ------------ -------------------------------- ------------------------------
  bMHC         5′-GCTGGGGCTGATGCGCCTAT-3′       5′-TGGGGATGGGTGGAGCGCAA-3′
  cActin       5′-GACGAGGAGACCACCGCCCT-3′       5′-ACCATAACTCCCTGGTGCCGC-3′
  GATA4        5′-AGCAGCTTCTGCGCCTGTGG-3′       5′-TGGGGGCAGAAGACGGAGGG-3′
  MEF2C        5′- TCCTGCAAATATGGCCCTAG-3′      5′- CCTGACACACCGGGATTGTT-3′
  Nkx2.5       5′-TCACCGGCCAAGTGTGCGTC-3′       5′-GCAGCGCGCACAGCTCTTTC-3′
  Troponin T   5′-GGAGCAGGAAGAAGCAGCTGTTGA-3′   5′-TTCTGCCCTGGTCTCCTCGGTC-3′
  GusB         5′-CAACGAGCCTGCGTCCCACC-3′       5′-ACGGAGCCCCCTTGTCTGCT-3′

###### 

Critical steps and troubleshooting of decellularization technique and valve competence, coronary circulation and pressure-volume assessments.

Table 3

                                    **Principal steps**                                                                                                                                                                                                                                                                                                                                                                                                                                        **Trouble shooting**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **Samples**   **Homogeneity**
  --------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- -----------------
  **Decellularization technique**   •Perfusion decellularization is performed with 1% sodium dodecyl sulfate (SDS) detergent in deionized water via antegrade coronary perfusion through the ascending aorta. Approximately 60 l of solution, during 4 days perfusion, is needed to decelullarize a human heart.•After SDS perfusion extensive rinsing with approximately 20 l of water followed by 10 l of penicillin-streptomycin-containing phosphate-buffered saline (PBS) is performed.   •The quality of SDS powder varies between brands. SDS solution should be completely clear without aggregates.•Pressure should be monitorized in order to avoid leaks through the translucent wall chamber because of overpressure.•Yellow-brown lipofuscin precipitates are observed within decellularized myocardium if overpressure during antegrade coronary perfusion                                                                                                                                         N=39          Yes
  **Valve competence**              •  Competency of valves was assed by macroscopic inspection, by filling with saline the ascending aorta and pulmonary arteries in the case of the semilunar valves (aortic and pulmonary), and by echocardiography.                                                                                                                                                                                                                                        •  To obtain adequate echocardiography images make sure the heart scaffold is fully submerged in 36 °C deionized water.                                                                                                                                                                                                                                                                                                                                                                                           N=5           Yes
  **Coronary circulation**          •Left and right coronary ostium are cannulated with a conventional cardiac surgery irrigating cannula. In our cases we used a Debakey 3 mm cannula.•The coronary sinus is also cannulated with a conventional retrograde cannula in order to drain the injected contrast media.                                                                                                                                                                            •An automatic contract injection was preferred over a manual standard technique as it allowed us to control of injection rate and amount of contrast to be delivered.•Angiographic runs had to be long enough to allow filling of the venous coronary system.                                                                                                                                                                                                                                                     N=5           Yes
  **Pressure-volume assesment**     •Ensure LV and RV are hermetically closed suturing all four cardiac valves in a fully closed position.•Soak the PV conductance catheter in a warm 36 °C saline for 30 min before measurements•Pressure and volume are modified by aspiration, followed by slow injection of isotonic saline with the use of 60 ml syringes.                                                                                                                                •Ensure the PV conductance catheter has all sensing electrodes within LV or RV. If all segments are not active adjust the catheter position until all segments are active. Sometimes a slight twisting of the catheter may be necessary to optimize loop morphology•Pressure data were digitally acquired continuously whereas volume was recoded at 1-mL intervals to obtain an optimal configuration.•Ensure the contralateral ventricle is empty when PV measurements are performed in the selected chamber.   N=8           Yes
